MAPK8 and cancer: SP600125, the most studied ATP-competitive JNK inhibitor, showed remarkable anticancer effects to inhibit the spherogenesis of MCF7 cells [49] or overcome multiple-drug resistance in cancers when applied in combination with traditional chemotherapeutic agents [52], but its role in sensitising cells to tamoxifen therapy is unknown.